Overview
- The University of Oxford has opened a 50‑participant Phase I study called BD‑Ebov, recruitment began on Monday and vaccinations are expected to start in the coming weeks pending regulatory clearance.
- The Serum Institute of India produced about 620,000 doses of the investigational ChAdOx1 BDBV vaccine within weeks and has supplied 4,000 doses for the Oxford trial.
- ChAdOx1 BDBV uses the same chimpanzee adenovirus vector platform used in the Oxford–AstraZeneca COVID‑19 vaccine and volunteers will be followed for up to a year with major safety signals expected to appear within weeks.
- The programme is backed by initial CEPI funding of roughly $8.6 million and teams are preparing staged trials in Uganda with MRC/UVRI and LSHTM partners subject to local approvals.
- Health officials warn that this early‑stage clinical work will not immediately change the course of the WHO‑declared PHEIC outbreak, which has produced large case and death counts and faces operational hurdles such as insecurity, strained health systems, diagnostics delays and community distrust.